

Janet E Pope

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7889158/janet-e-pope-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

540
papers

25,699
citations

75
h-index

142
g-index

615
ext. papers

31,520
ext. citations

4.9
avg, IF

7.04
L-index

#	Paper	IF	Citations
540	2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2737-47		1636
539	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1747-55	2.4	1109
538	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 685-699	2.4	851
537	Mortality in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2550-7		751
536	Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. <i>New England Journal of Medicine</i> , 1997 , 337, 382-7	59.2	608
535	CIP2A inhibits PP2A in human malignancies. <i>Cell</i> , 2007 , 130, 51-62	56.2	591
534	Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. <i>Arthritis and Rheumatism</i> , 2004 , 50, 3985-93		533
533	A randomized trial of arthroscopic surgery for osteoarthritis of the knee. <i>New England Journal of Medicine</i> , 2008 , 359, 1097-107	59.2	483
532	The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 480-9	2.4	477
531	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1340-9	2.4	444
530	Novel treatment strategies in rheumatoid arthritis. <i>Lancet, The</i> , 2017 , 389, 2338-2348	40	407
529	Highly effective visible-light-induced H ₂ generation by single-layer 1T-MoS ₂ and a nanocomposite of few-layer 2H-MoS ₂ with heavily nitrogenated graphene. <i>Angewandte Chemie - International Edition</i> , 2013 , 52, 13057-61	16.4	378
528	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. <i>Lancet, The</i> , 2016 , 387, 2630-2640	40	359
527	Systemic sclerosis. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15002	51.1	351
526	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 32-8	2.4	304
525	A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1351-8		302
524	An international cohort study of cancer in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005 , 52, 1481-90		292

523	Psoriasis and pustular dermatitis triggered by TNF- α inhibitors in patients with rheumatologic conditions. <i>Archives of Dermatology</i> , 2007 , 143, 223-31		219
522	Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2001 , 44, 1841-7		206
521	Cancer risk in systemic lupus: an updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013 , 42, 130-5	15.5	194
520	Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 11-18	2.3	190
519	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 212-220	2.4	172
518	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017 , 8, 16021	17.4	171
517	Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. <i>Journal of Rheumatology</i> , 2012 , 39, 1559-82	4.1	169
516	Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. <i>Rheumatology</i> , 2005 , 44, 145-50	3.9	155
515	A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. <i>Osteoarthritis and Cartilage</i> , 2002 , 10, 506-17	6.2	153
514	ImmunoChip analysis identifies multiple susceptibility loci for systemic sclerosis. <i>American Journal of Human Genetics</i> , 2014 , 94, 47-61	11	151
513	Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. <i>Rheumatology</i> , 2011 , 50, 762-7	3.9	145
512	Determinants of morbidity and mortality of systemic sclerosis in Canada. <i>Seminars in Arthritis and Rheumatism</i> , 2010 , 39, 269-77	5.3	142
511	Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016). <i>Canadian Journal of Cardiology</i> , 2016 , 32, S35-65	3.8	138
510	Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. <i>Canadian Journal of Cardiology</i> , 2011 , 27, 635-62	3.8	135
509	Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). <i>Rheumatology</i> , 2010 , 49, 1683-93	3.9	135
508	Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2013 , 65, 353-61	4.7	130
507	Campylobacter reactive arthritis: a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2007 , 37, 48-55	5.3	130
506	Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. <i>Canadian Journal of Cardiology</i> , 2013 , 29, 1553-68	3.8	126

505	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. <i>Arthritis and Rheumatology</i> , 2017 , 69, 362-375	9.5	125
504	Treatment Algorithms for Systemic Sclerosis According to Experts. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1820-1828	9.5	120
503	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2020 , 8, 963-974	35.1	112
502	Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. <i>Arthritis and Rheumatism</i> , 2011 , 63, 1479-85		111
501	Occupational and environmental exposures and risk of systemic lupus erythematosus: silica, sunlight, solvents. <i>Rheumatology</i> , 2010 , 49, 2172-80	3.9	109
500	Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. <i>Arthritis and Rheumatism</i> , 2004 , 51, 738-45		109
499	Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. <i>Lupus</i> , 2011 , 20, 1345-55	2.6	108
498	Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1796-804		107
497	Digital ulcers: overt vascular disease in systemic sclerosis. <i>Rheumatology</i> , 2009 , 48 Suppl 3, iii19-24	3.9	106
496	Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2014 , 66, 1653-61	4.7	104
495	Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. <i>Journal of Rheumatology</i> , 2012 , 39, 1583-602	4.1	104
494	Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. <i>Rheumatology</i> , 2012 , 51, 2204-14	3.9	102
493	The minimally important difference for the health assessment questionnaire in rheumatoid arthritis clinical practice is smaller than in randomized controlled trials. <i>Journal of Rheumatology</i> , 2009 , 36, 254-9	4.1	98
492	Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1222-8	2.4	98
491	Associations with digital ulcers in a large cohort of systemic sclerosis: results from the Canadian Scleroderma Research Group registry. <i>Arthritis Care and Research</i> , 2011 , 63, 142-9	4.7	97
490	Health-related quality of life in systemic sclerosis: a systematic review. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1112-20		97
489	Employment and work disability in systemic lupus erythematosus: a systematic review. <i>Rheumatology</i> , 2009 , 48, 281-4	3.9	96
488	The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review. <i>Journal of Rheumatology</i> , 2013 , 40, 1545-56	4.1	94

487	Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 42, 179-85	5.3	93
486	The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. <i>Journal of Rheumatology</i> , 2009 , 36, 1200-8	4.1	92
485	The diagnosis and treatment of Raynaud's phenomenon: a practical approach. <i>Drugs</i> , 2007 , 67, 517-25	12.1	92
484	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020 , 72, 125-136	9.5	92
483	Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1067-1077	9.5	91
482	Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts. <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 42, 42-55	5.3	91
481	Comparison of the PHQ-9 and CES-D depression scales in systemic sclerosis: internal consistency reliability, convergent validity and clinical correlates. <i>Rheumatology</i> , 2010 , 49, 789-96	3.9	91
480	Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database. <i>Journal of Rheumatology</i> , 2009 , 36, 2737-43	4.1	90
479	MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. <i>Arthritis and Rheumatism</i> , 2009 , 60, 870-7		89
478	Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. <i>Journal of Rheumatology</i> , 2015 , 42, 1767-80	4.1	88
477	Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. <i>Arthritis Care and Research</i> , 2012 , 64, 519-24	4.7	87
476	Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3547-51		87
475	A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. <i>Medical Science Monitor</i> , 2011 , 17, CR347-54	3.2	85
474	A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. <i>Archives of Internal Medicine</i> , 1993 , 153, 477-484		84
473	Polyautoimmunity and familial autoimmunity in systemic sclerosis. <i>Journal of Autoimmunity</i> , 2008 , 31, 156-9	15.5	83
472	Prevalence of hearing loss in the United States by industry. <i>American Journal of Industrial Medicine</i> , 2013 , 56, 670-81	2.7	82
471	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. <i>BMJ Open</i> , 2013 , 3,	3	82
470	Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study. <i>Journal of Rheumatology</i> , 2010 , 37, 38-44	4.1	81

469	Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2012 , 14, R50	5.7	80
468	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 270-276	2.4	79
467	A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. <i>Osteoarthritis and Cartilage</i> , 2002 , 10, 518-27	6.2	78
466	All-cause hospitalizations in systemic lupus erythematosus from a large Canadian referral centre. <i>Rheumatology</i> , 2013 , 52, 905-9	3.9	76
465	Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. <i>Arthritis Care and Research</i> , 2013 , 65, 1460-71	4.7	74
464	Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Sub-domain (SCTC-GI) and Scleroderma Clinical Trials Consortium Health Assessment Questionnaire (SCTC-HAQ)	4.7	74
463	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 315, 1975-88	27.4	74
462	Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. <i>Arthritis Care and Research</i> , 2012 , 64, 1405-14	4.7	72
461	The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice. <i>Journal of Rheumatology</i> , 2008 , 35, 2339-43	4.1	72
460	Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 504-9		72
459	A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2008 , 27, 77-83	3.9	71
458	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 299-311	9.5	69
457	Treatment Algorithms in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2015 , 67, 1237-1245	4.7	67
456	Psychological health and well-being in systemic sclerosis: State of the science and consensus research agenda. <i>Arthritis Care and Research</i> , 2010 , 62, 1181-9	4.7	66
455	A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2014 , 16, 435	5.7	65
454	Development of a provisional core set of response measures for clinical trials of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 703-9	2.4	65
453	The development of rheumatoid arthritis after recombinant hepatitis B vaccination. <i>Journal of Rheumatology</i> , 1998 , 25, 1687-93	4.1	65
452	Validation of potential classification criteria for systemic sclerosis. <i>Arthritis Care and Research</i> , 2012 , 64, 358-67	4.7	64

451	Quality of life in systemic sclerosis: psychometric properties of the World Health Organization Disability Assessment Schedule II. <i>Arthritis and Rheumatism</i> , 2008 , 59, 270-8		64
450	Requirement of transforming growth factor beta-activated kinase 1 for transforming growth factor beta-induced alpha-smooth muscle actin expression and extracellular matrix contraction in fibroblasts. <i>Arthritis and Rheumatism</i> , 2009 , 60, 234-41		63
449	Reliability and validity of the center for epidemiologic studies depression scale in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 438-43		63
448	Work disability in systemic lupus erythematosus is prevalent and associated with socio-demographic and disease related factors. <i>Lupus</i> , 2009 , 18, 1281-8	2.6	62
447	Loss of PTEN expression by dermal fibroblasts causes skin fibrosis. <i>Journal of Investigative Dermatology</i> , 2011 , 131, 1996-2003	4.3	62
446	Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides. <i>Journal of Rheumatology</i> , 2014 , 41, 270-9	4.1	61
445	Accuracy of Canadian health administrative databases in identifying patients with rheumatoid arthritis: a validation study using the medical records of rheumatologists. <i>Arthritis Care and Research</i> , 2013 , 65, 1582-91	4.7	61
444	A study of the frequency of pericardial and pleural effusions in scleroderma. <i>British Journal of Rheumatology</i> , 1998 , 37, 1320-3		60
443	Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 1063-70	4.6	59
442	Cigarette smoking in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 230-8		59
441	Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant. <i>American Journal of Medicine</i> , 1991 , 90, 299-309	2.4	59
440	Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies. <i>Journal of Cutaneous Medicine and Surgery</i> , 2019 , 23, 50-74	1.6	58
439	Systemic sclerosis - continuing progress in developing clinical measures of response. <i>Journal of Rheumatology</i> , 2007 , 34, 1194-200	4.1	58
438	Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3420-9		57
437	Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. <i>Journal of Rheumatology</i> , 2009 , 36, 323-9	4.1	57
436	Mortality related to cerebrovascular disease in systemic lupus erythematosus. <i>Lupus</i> , 2006 , 15, 835-9	2.6	57
435	Prevalence, severity, and clinical correlates of pain in patients with systemic sclerosis. <i>Arthritis Care and Research</i> , 2010 , 62, 409-17	4.7	56
434	Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. <i>Journal of Rheumatology</i> , 2005 , 32, 1273-8	4.1	55

433	Quality of life in patients with systemic sclerosis compared to the general population and patients with other chronic conditions. <i>Journal of Rheumatology</i> , 2009 , 36, 768-72	4.1	54
432	An update in pulmonary hypertension in systemic lupus erythematosus - do we need to know about it?. <i>Lupus</i> , 2008 , 17, 274-7	2.6	54
431	Determining the Minimally Important Difference in the Clinical Disease Activity Index for Improvement and Worsening in Early Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2015 , 67, 1345-53	4.7	53
430	Incidence and predictors of secondary fibromyalgia in an early arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 949-54	2.4	53
429	Sex differences in pain scores and localization in inflammatory arthritis: a systematic review and metaanalysis. <i>Journal of Rheumatology</i> , 2012 , 39, 1221-30	4.1	53
428	Office capillaroscopy in systemic sclerosis. <i>Clinical Rheumatology</i> , 2007 , 26, 1268-74	3.9	53
427	Stand Up and Be Counted: Measuring and Mapping the Rheumatology Workforce in Canada. <i>Journal of Rheumatology</i> , 2017 , 44, 248-257	4.1	52
426	Trends in Excess Mortality Among Patients With Rheumatoid Arthritis in Ontario, Canada. <i>Arthritis Care and Research</i> , 2015 , 67, 1047-53	4.7	52
425	Corticosteroids and the risk of scleroderma renal crisis: a systematic review. <i>Rheumatology International</i> , 2012 , 32, 645-53	3.6	52
424	2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group. <i>Arthritis Care and Research</i> , 2015 , 67, 582-7	4.7	51
423	Association of smoking with cutaneous manifestations in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2013 , 65, 1275-80	4.7	51
422	The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36. <i>Journal of Rheumatology</i> , 2009 , 36, 2231-7	4.1	51
421	Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. <i>Rheumatology</i> , 2017 , 56, 1144-1153	3.9	50
420	Does the impact of board independence on large bank risks change after the global financial crisis?. <i>Journal of Corporate Finance</i> , 2017 , 44, 149-166	3.7	50
419	The Canadian systemic sclerosis oral health study: orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with the general population. <i>Rheumatology</i> , 2014 , 53, 1386-94	3.9	50
418	The cost of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 119-23		50
417	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 71-87	2.4	50
416	Prognosis of seronegative patients in a large prospective cohort of patients with early inflammatory arthritis. <i>Journal of Rheumatology</i> , 2014 , 41, 2361-9	4.1	49

415	Work disability in systemic sclerosis. <i>Journal of Rheumatology</i> , 2009 , 36, 2481-6	4.1	48
414	Sociodemographic, disease, and symptom correlates of fatigue in systemic sclerosis: evidence from a sample of 659 Canadian Scleroderma Research Group Registry patients. <i>Arthritis and Rheumatism</i> , 2009 , 61, 966-73		48
413	Update on indices of disease activity in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2007 , 37, 93-8	5.3	48
412	Variability of skin scores and clinical measurements in scleroderma. <i>Journal of Rheumatology</i> , 1995 , 22, 1271-6	4.1	48
411	Scleroderma overlap syndromes. <i>Current Opinion in Rheumatology</i> , 2002 , 14, 704-10	5.3	47
410	Minimally important difference for patient-reported outcomes in psoriatic arthritis: Health Assessment Questionnaire and pain, fatigue, and global visual analog scales. <i>Journal of Rheumatology</i> , 2010 , 37, 1024-8	4.1	45
409	The development of systemic sclerosis classification criteria. <i>Clinical Rheumatology</i> , 2007 , 26, 1401-9	3.9	45
408	Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 867-75		45
407	Influence of ethnicity on childhood-onset systemic lupus erythematosus: results from a multiethnic multicenter Canadian cohort. <i>Arthritis Care and Research</i> , 2013 , 65, 152-60	4.7	44
406	The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma. <i>Journal of Rheumatology</i> , 2010 , 37, 591-8	4.1	44
405	Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis. <i>Journal of Rheumatology</i> , 2011 , 38, 1326-8	4.1	44
404	Test-retest reliability of patient global assessment and physician global assessment in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2009 , 36, 2178-82	4.1	44
403	Race/ethnicity and cancer occurrence in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005 , 53, 781-4		44
402	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 648-656	2.4	43
401	Antinuclear antibody-negative systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 44, 680-6	5.3	43
400	Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. <i>Clinical Rheumatology</i> , 2014 , 33, 207-14	3.9	43
399	Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis. <i>Journal of Rheumatology</i> , 2013 , 40, 850-8	4.1	43
398	CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1871-1878	9.5	43

397	Osteoporosis in scleroderma. <i>Seminars in Arthritis and Rheumatism</i> , 2005 , 34, 678-82	5.3	42
396	Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set. <i>RMD Open</i> , 2016 , 2, e000225	5.9	42
395	Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort. <i>Scandinavian Journal of Rheumatology</i> , 2014 , 43, 217-20	1.9	41
394	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , 2012 , 64, 351-7	4.7	41
393	Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review. <i>Rheumatology</i> , 2011 , 50, 311-6	3.9	41
392	Clinical correlates of quality of life in systemic sclerosis measured with the World Health Organization Disability Assessment Schedule II. <i>Arthritis and Rheumatism</i> , 2008 , 59, 279-84		41
391	Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians. <i>Journal of Clinical Epidemiology</i> , 2002 , 55, 488-97	5.7	41
390	Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review. <i>Advances in Therapy</i> , 2018 , 35, 1535-1563	4.1	40
389	Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects. <i>Journal of Rheumatology</i> , 2014 , 41, 2179-85	4.1	40
388	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 706-14	5.7	40
387	Quality care in seniors with new-onset rheumatoid arthritis: a Canadian perspective. <i>Arthritis Care and Research</i> , 2011 , 63, 53-7	4.7	39
386	Musculoskeletal involvement in scleroderma. <i>Rheumatic Disease Clinics of North America</i> , 2003 , 29, 391-408		39
385	Calcinosis is associated with digital ischaemia in systemic sclerosis-a longitudinal study. <i>Rheumatology</i> , 2016 , 55, 2148-2155	3.9	39
384	Erectile dysfunction associated with scleroderma: a case-control study of men with scleroderma and rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2004 , 31, 508-13	4.1	39
383	Other manifestations of mixed connective tissue disease. <i>Rheumatic Disease Clinics of North America</i> , 2005 , 31, 519-33, vii	2.4	38
382	Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis. <i>Journal of Rheumatology</i> , 2002 , 29, 1867-73	4.1	38
381	Outcome measurements in scleroderma: results from a delphi exercise. <i>Journal of Rheumatology</i> , 2007 , 34, 501-9	4.1	38
380	Psoriasis and Smoking: A Systematic Literature Review and Meta-Analysis With Qualitative Analysis of Effect of Smoking on Psoriasis Severity. <i>Journal of Cutaneous Medicine and Surgery</i> , 2016 , 20, 221-7	1.6	37

379	Cervical spine involvement in rheumatoid arthritis over time: results from a meta-analysis. <i>Arthritis Research and Therapy</i> , 2015 , 17, 148	5.7	37
378	Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: clinical associations. <i>Medicine (United States)</i> , 2016 , 95, e4713	1.8	36
377	Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. <i>Arthritis Research and Therapy</i> , 2014 , 16, 493	5.7	36
376	Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases. <i>Journal of Rheumatology</i> , 2014 , 41, 792-8	4.1	36
375	Differences in autoantibody profiles and disease activity and damage scores between childhood- and adult-onset systemic lupus erythematosus: a meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 42, 271-80	5.3	36
374	A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles. <i>Genes and Immunity</i> , 2011 , 12, 51-8	4.4	36
373	The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis. <i>Rheumatology</i> , 2009 , 48, 791-5	3.9	36
372	Arthritis risk after acute bacterial gastroenteritis. <i>Rheumatology</i> , 2008 , 47, 200-4	3.9	36
371	Outcome measurement in scleroderma clinical trials. <i>Seminars in Arthritis and Rheumatism</i> , 1993 , 23, 22-33	5.3	36
370	The Canadian Systemic Sclerosis Oral Health Study IV: oral radiographic manifestations in systemic sclerosis compared with the general population. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015 , 120, 104-11	2	35
369	The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1003-8	2.4	35
368	RFC1 80G>A is a genetic determinant of methotrexate efficacy in rheumatoid arthritis: a human genome epidemiologic review and meta-analysis of observational studies. <i>Arthritis and Rheumatology</i> , 2014 , 66, 1111-20	9.5	35
367	Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 191-7	2.4	35
366	Frailty index to measure health status in people with systemic sclerosis. <i>Journal of Rheumatology</i> , 2014 , 41, 698-705	4.1	35
365	Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis--results from the Canadian Early Arthritis Cohort (CATCH). <i>Journal of Rheumatology</i> , 2014 , 41, 2161-6	4.1	35
364	The Canadian Early Arthritis Cohort (CATCH): patients with new-onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activity. <i>Journal of Rheumatology</i> , 2012 , 39, 2071-80	4.1	35
363	Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. <i>Rheumatology</i> , 2012 , 51, 1662-9	3.9	35
362	Association of pruritus with quality of life and disability in systemic sclerosis. <i>Arthritis Care and Research</i> , 2010 , 62, 1489-95	4.7	35

361	Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. <i>The Cochrane Library</i> , 2000 , CD000953	5.2	35
360	Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials. <i>Arthritis Care and Research</i> , 2015 , 67, 754-64	4.7	34
359	The Canadian methotrexate and etanercept outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 2144-51	2.4	34
358	Sociodemographic and disease correlates of body image distress among patients with systemic sclerosis. <i>PLoS ONE</i> , 2012 , 7, e33281	3.7	34
357	Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. <i>Journal of Rheumatology</i> , 2012 , 39, 787-94	4.1	34
356	Reduced proportions of natural killer T cells are present in the relatives of lupus patients and are associated with autoimmunity. <i>Arthritis Research and Therapy</i> , 2008 , 10, R108	5.7	34
355	Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 41, 81-9	5.3	33
354	Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. <i>Journal of Rheumatology</i> , 2009 , 36, 1421-8	4.1	33
353	(Not) talking about sex: a systematic comparison of sexual impairment in women with systemic sclerosis and other chronic disease samples. <i>Rheumatology</i> , 2009 , 48, 1300-3	3.9	33
352	Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. <i>Journal of the American Academy of Dermatology</i> , 2009 , 60, 402-11	4.5	33
351	A gradient of acute gastroenteritis was characterized, to assess risk of long-term health sequelae after drinking bacterial-contaminated water. <i>Journal of Clinical Epidemiology</i> , 2006 , 59, 421-8	5.7	33
350	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018 , 45, 1426-1439	4.1	33
349	Frequency of adverse drug reactions in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2003 , 30, 480-4	4.1	33
348	Raynaud's phenomenon-an update on diagnosis, classification and management. <i>Clinical Rheumatology</i> , 2019 , 38, 3317-3330	3.9	32
347	Anticitrullinated protein antibodies and rheumatoid factor fluctuate in early inflammatory arthritis and do not predict clinical outcomes. <i>Journal of Rheumatology</i> , 2013 , 40, 1259-67	4.1	32
346	Relationship between disease characteristics and orofacial manifestations in systemic sclerosis: Canadian Systemic Sclerosis Oral Health Study III. <i>Arthritis Care and Research</i> , 2015 , 67, 681-90	4.7	31
345	Anti-fibrillar antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis. <i>Journal of Rheumatology</i> , 2011 , 38, 1622-30	4.1	31
344	The chemokine CCL18 generates adaptive regulatory T cells from memory CD4+ T cells of healthy but not allergic subjects. <i>FASEB Journal</i> , 2010 , 24, 5063-72	0.9	31

343	Development and validation of the brief-satisfaction with appearance scale for systemic sclerosis. <i>Arthritis Care and Research</i> , 2010 , 62, 1779-86	4.7	31
342	Prescribing trends in disease modifying antirheumatic drugs for rheumatoid arthritis: a survey of practicing Canadian rheumatologists. <i>Journal of Rheumatology</i> , 2002 , 29, 255-60	4.1	31
341	Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA. <i>Clinica Chimica Acta</i> , 2011 , 412, 1937-43	6.2	30
340	Treatment of early rheumatoid arthritis: concepts in management. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 40, 371-88	5.3	30
339	Remission in early rheumatoid arthritis -- a comparison of new ACR/EULAR remission criteria to established criteria. <i>Journal of Rheumatology</i> , 2012 , 39, 1155-8	4.1	30
338	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 618-625	2.4	30
337	Interleukin 6 in systemic sclerosis and potential implications for targeted therapy. <i>Journal of Rheumatology</i> , 2012 , 39, 1120-4	4.1	29
336	Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial. <i>Arthritis Care and Research</i> , 2013 , 65, 1401-9	4.7	29
335	Canadian recommendations for use of methotrexate in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2010 , 37, 1422-30	4.1	29
334	Disability in systemic sclerosis -- a longitudinal observational study. <i>Journal of Rheumatology</i> , 2011 , 38, 685-92	4.1	29
333	The lack of associations between rheumatoid arthritis and both nulliparity and infertility. <i>Seminars in Arthritis and Rheumatism</i> , 1999 , 28, 342-50	5.3	29
332	Monitoring of Osteonecrosis in Systemic Lupus Erythematosus: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2018 , 45, 1462-1476	4.1	29
331	Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 46, 767-774	5.3	28
330	Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group. <i>Journal of Rheumatology</i> , 2012 , 39, 524-31	4.1	28
329	The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, 122-34	2.2	28
328	Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists. <i>Clinical Rheumatology</i> , 2015 , 34, 1427-33	3.9	27
327	Healthcare cost and loss of productivity in a Canadian population of patients with and without lupus nephritis. <i>Journal of Rheumatology</i> , 2011 , 38, 658-66	4.1	27
326	The Frequency of Scleroderma Renal Crisis over Time: A Metaanalysis. <i>Journal of Rheumatology</i> , 2016 , 43, 1350-5	4.1	27

325	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. <i>Rheumatology</i> , 2018 , 57, 1623-1631	3.9	26
324	Time to disease-modifying antirheumatic drug treatment in rheumatoid arthritis and its predictors: a national, multicenter, retrospective cohort. <i>Journal of Rheumatology</i> , 2012 , 39, 2088-97	4.1	26
323	Prevalence of current, 12-month and lifetime major depressive disorder among patients with systemic sclerosis. <i>Rheumatology</i> , 2013 , 52, 669-75	3.9	26
322	Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1765-70		26
321	New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). <i>Clinical and Experimental Rheumatology</i> , 2012 , 30, S23-9	2.2	26
320	Work disability in scleroderma is greater than in rheumatoid arthritis and is predicted by high HAQ scores. <i>Open Rheumatology Journal</i> , 2008 , 2, 44-52	0.2	26
319	Discordance between patient and physician assessments of disease severity in systemic sclerosis. <i>Journal of Rheumatology</i> , 2010 , 37, 2307-12	4.1	25
318	Social responsibility of hospitals: an Indian context. <i>Social Responsibility Journal</i> , 2010 , 6, 268-285	3	25
317	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report. <i>Journal of Scleroderma and Related Disorders</i> , 2018 , 3, 249-252	2.3	25
316	RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. <i>Respiratory Medicine</i> , 2017 , 122 Suppl 1, S14-S17	4.1	24
315	Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH). <i>PLoS ONE</i> , 2015 , 10, e0135327	3.7	24
314	New Classification Criteria for Systemic Sclerosis (Scleroderma). <i>Rheumatic Disease Clinics of North America</i> , 2015 , 41, 383-98	2.4	24
313	Determining best practices in early rheumatoid arthritis by comparing differences in treatment at sites in the Canadian Early Arthritis Cohort. <i>Journal of Rheumatology</i> , 2013 , 40, 1823-30	4.1	24
312	The relationship of dyspnoea to function and quality of life in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 644-50	2.4	24
311	Position Statement: A Pragmatic Approach for Medical Cannabis and Patients with Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2019 , 46, 532-538	4.1	23
310	Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review. <i>Immunotherapy</i> , 2019 , 11, 737-754	3.8	23
309	What Does the COVID-19 Pandemic Mean for Rheumatology Patients?. <i>Current Treatment Options in Rheumatology</i> , 2020 , 6, 1-4	1.3	23
308	Are there differences between young- and older-onset early inflammatory arthritis and do these impact outcomes? An analysis from the CATCH cohort. <i>Rheumatology</i> , 2014 , 53, 1075-86	3.9	23

307	Clinical and serologic factors associated with lupus pleuritis. <i>Journal of Rheumatology</i> , 2010 , 37, 747-53	4.1	23
306	Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis. <i>Journal of Rheumatology</i> , 2011 , 38, 1925-30	4.1	23
305	The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. <i>British Journal of Rheumatology</i> , 2004 , 43, 472-8		23
304	Validation of the Self-Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2016 , 68, 1195-200	4.7	23
303	Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort. <i>Autoimmunity Reviews</i> , 2020 , 19, 102595	13.6	22
302	Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort. <i>Rheumatology</i> , 2016 , 55, 1751-62	3.9	22
301	The minimally important difference for patient-reported outcomes in spondyloarthropathies including pain, fatigue, sleep, and Health Assessment Questionnaire. <i>Journal of Rheumatology</i> , 2010 , 37, 816-22	4.1	22
300	Time to diagnosis in systemic sclerosis: is sex a factor?. <i>Arthritis and Rheumatism</i> , 2009 , 61, 274-8		22
299	Overweight, Obesity, and the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results From a Multicenter Prospective Cohort Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1185-1191	4.7	22
298	A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists. <i>Journal of Rheumatology</i> , 2000 , 27, 1506-12	4.1	22
297	The frequency of and associations with hospitalization secondary to lupus flares from the 1000 Faces of Lupus Canadian cohort. <i>Lupus</i> , 2013 , 22, 1341-8	2.6	21
296	Is serum albumin a marker of malnutrition in chronic disease? The scleroderma paradigm. <i>Journal of the American College of Nutrition</i> , 2010 , 29, 144-51	3.5	21
295	Self-reported flaring varies during the menstrual cycle in systemic lupus erythematosus compared with rheumatoid arthritis and fibromyalgia. <i>Rheumatology</i> , 2011 , 50, 703-8	3.9	21
294	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019 , 71, 964-971	9.5	21
293	The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study. <i>Journal of Pain and Symptom Management</i> , 2016 , 52, 43-53	4.8	20
292	Effect of age at menopause on disease presentation in early rheumatoid arthritis: results from the Canadian Early Arthritis Cohort. <i>Arthritis Care and Research</i> , 2015 , 67, 616-23	4.7	20
291	Clinical correlates of sleep problems in systemic sclerosis: the prominent role of pain. <i>Rheumatology</i> , 2011 , 50, 921-5	3.9	20
290	The association of body image dissatisfaction and pain with reduced sexual function in women with systemic sclerosis. <i>Rheumatology</i> , 2011 , 50, 1125-30	3.9	20

289	Reports of abnormal cervical cancer screening tests in systemic sclerosis. <i>Rheumatology</i> , 2009 , 48, 149-51.	3.9	20
288	Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis. <i>Advances in Therapy</i> , 2020 , 37, 2356-2372	4.1	20
287	Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis. <i>RMD Open</i> , 2017 , 3, e000371	5.9	19
286	Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials. <i>Rheumatology International</i> , 2013 , 33, 1105-20	3.6	19
285	Scleroderma treatment differs between experts and general rheumatologists. <i>Arthritis and Rheumatism</i> , 2006 , 55, 138-45		19
284	Associations Between Methotrexate Use and the Risk of Cardiovascular Events in Patients with Elderly-onset Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019 , 46, 467-474	4.1	19
283	C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 219-229	5.3	19
282	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1242-1248	2.4	18
281	Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 45, 184-9	5.3	18
280	There is a need for new systemic sclerosis subset criteria. A content analytic approach. <i>Scandinavian Journal of Rheumatology</i> , 2018 , 47, 62-70	1.9	18
279	Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 42-49	2.3	18
278	A systematic review of viral exposures as a risk for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 587-596	5.3	18
277	Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	17
276	Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 128-132	2.4	17
275	Relationship Between Disease Characteristics and Oral Radiologic Findings in Systemic Sclerosis: Results From a Canadian Oral Health Study. <i>Arthritis Care and Research</i> , 2016 , 68, 673-80	4.7	17
274	Diagnosis and Management of Systemic Sclerosis: A Practical Approach. <i>Drugs</i> , 2016 , 76, 203-13	12.1	17
273	A review of the effects of statins in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 698-705	5.3	17
272	Calcium channel blockers for primary and secondary Raynaud's phenomenon. <i>The Cochrane Library</i> , 2017 , 12, CD000467	5.2	17

271	Association of health-related quality of life in childhood-onset systemic lupus erythematosus with ethnicity: results from a multiethnic multicenter Canadian cohort. <i>Arthritis Care and Research</i> , 2014 , 66, 1767-74	4.7	17
270	Care gap in patients with early inflammatory arthritis with a high fracture risk identified using FRAX(®). <i>Journal of Rheumatology</i> , 2010 , 37, 2221-5	4.1	17
269	High rates of depressive symptoms among patients with systemic sclerosis are not explained by differential reporting of somatic symptoms. <i>Arthritis and Rheumatism</i> , 2008 , 59, 431-7		17
268	Early intensive treatment of clubfoot. 75 feet followed for 6-11 years. <i>Acta Orthopaedica</i> , 1992 , 63, 183-8		17
267	Current and future status of JAK inhibitors. <i>Lancet, The</i> , 2021 , 398, 803-816	4.0	17
266	The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative. <i>Clinical Rheumatology</i> , 2016 , 35, 759-63	3.9	16
265	Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 807-816	2.4	16
264	The Canadian systemic sclerosis oral health study II: the relationship between oral and global health-related quality of life in systemic sclerosis. <i>Rheumatology</i> , 2015 , 54, 692-6	3.9	16
263	Management of Fatigue in Rheumatoid Arthritis. <i>RMD Open</i> , 2020 , 6,	5.9	16
262	Measuring Disease Activity and Damage with Validated Metrics: A Systematic Review on Mortality and Damage in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018 , 45, 1448-1461	4.1	16
261	The frequency of uveitis in patients with juvenile inflammatory rheumatic diseases. <i>Joint Bone Spine</i> , 2019 , 86, 685-690	2.9	16
260	Therapeutic drug monitoring in rheumatic diseases: utile or futile?. <i>Rheumatology</i> , 2014 , 53, 988-97	3.9	16
259	Autoantibodies to the Rpp25 component of the Th/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests. <i>Journal of Rheumatology</i> , 2014 , 41, 1334-43	4.1	16
258	Longitudinal study of renal function in systemic sclerosis. <i>Journal of Rheumatology</i> , 2012 , 39, 1829-34	4.1	16
257	Clinical correlates of self-reported physical health status in systemic sclerosis. <i>Journal of Rheumatology</i> , 2009 , 36, 1226-9	4.1	16
256	Assessment of endpoints in pulmonary arterial hypertension associated with connective tissue disease. <i>Current Opinion in Pulmonary Medicine</i> , 2010 , 16 Suppl 1, S27-34	3	16
255	Carotid Artery Atherosclerosis in Patients with Active Rheumatoid Arthritis: Predictors of Plaque Occurrence and Progression Over 24 Weeks. <i>Open Rheumatology Journal</i> , 2016 , 10, 49-59	0.2	16
254	Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. <i>Arthritis Research and Therapy</i> , 2019 , 21, 263	5.7	16

253	Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. <i>Arthritis Research and Therapy</i> , 2019 , 21, 272	5.7	16
252	Ocular Manifestations in Rheumatoid Arthritis, Connective Tissue Disease, and Vasculitis: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2021 , 48, 25-34	4.1	16
251	The frequency and significance of anticardiolipin antibodies in scleroderma. <i>Journal of Rheumatology</i> , 2000 , 27, 1450-2	4.1	16
250	Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype. <i>Autoimmunity Reviews</i> , 2018 , 17, 267-275	13.6	15
249	Using Optimal Test Assembly Methods for Shortening Patient-Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scale-6: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2016 , 68, 1704-1713	4.7	15
248	Measuring the Rheumatology Workforce in Canada: A Literature Review. <i>Journal of Rheumatology</i> , 2016 , 43, 1121-9	4.1	15
247	Does socioeconomic status affect outcomes in early inflammatory arthritis? Data from a canadian multisite suspected rheumatoid arthritis inception cohort. <i>Journal of Rheumatology</i> , 2015 , 42, 46-54	4.1	15
246	Association of severe inflammatory polyarthritis in primary Sjögren's syndrome: clinical, serologic, and HLA analysis. <i>Journal of Rheumatology</i> , 2009 , 36, 1937-42	4.1	15
245	Ten-year absolute fracture risk and hip bone strength in Canadian women with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2012 , 39, 1378-84	4.1	15
244	What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG). <i>Rheumatology International</i> , 2010 , 30, 1205-10	3.6	15
243	Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. <i>Rheumatology</i> , 2008 , 47, 1367-72	3.9	15
242	Sexual activity and impairment in women with systemic sclerosis compared to women from a general population sample. <i>PLoS ONE</i> , 2012 , 7, e52129	3.7	15
241	Antifibrillar Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2017 , 44, 799-805	4.1	14
240	Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary. <i>Journal of Rheumatology</i> , 2019 , 46, 751-754	4.1	14
239	Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018 , 57, 813-817	3.9	14
238	Rates and correlates of sexual activity and impairment among women with systemic sclerosis. <i>Arthritis Care and Research</i> , 2012 , 64, 340-50	4.7	14
237	Influence of somatic symptoms on Patient Health Questionnaire-9 depression scores among patients with systemic sclerosis compared to a healthy general population sample. <i>Arthritis Care and Research</i> , 2012 , 64, 1195-201	4.7	14
236	Low socioeconomic status (measured by education) and outcomes in systemic sclerosis: data from the Canadian Scleroderma Research Group. <i>Journal of Rheumatology</i> , 2013 , 40, 447-54	4.1	14

235	The Relationship Between Function and Disease Activity as Measured by the HAQ and DAS28 Varies Over Time and by Rheumatoid Factor Status in Early Inflammatory Arthritis (EIA). Results from the CATCH Cohort. <i>Open Rheumatology Journal</i> , 2013 , 7, 58-63	0.2	14
234	Treatment of systemic sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 1996 , 22, 893-907	2.4	14
233	Influence of Education on Disease Activity and Damage in Systemic Lupus Erythematosus: Data From the 1000 Canadian Faces of Lupus. <i>Arthritis Care and Research</i> , 2017 , 69, 124-132	4.7	13
232	The effect of rheumatoid arthritis-associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis. <i>Rheumatology</i> , 2017 , 56, 768-776	3.9	13
231	Methotrexate withdrawal in patients with rheumatoid arthritis who achieve low disease activity with tofacitinib modified-release 11 mg once daily plus methotrexate (ORAL Shift): a randomised, phase 3b/4, non-inferiority trial. <i>Lancet Rheumatology, The</i> , 2019 , 1, e23-e34	14.2	13
230	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. <i>Arthritis Research and Therapy</i> , 2016 , 18, 20	5.7	13
229	Patient-Reported Outcome Measures in Systemic Sclerosis (Scleroderma). <i>Rheumatic Disease Clinics of North America</i> , 2016 , 42, 301-16	2.4	13
228	Factors associated with time to diagnosis in early rheumatoid arthritis. <i>Rheumatology International</i> , 2014 , 34, 85-92	3.6	13
227	Early management of newly diagnosed rheumatoid arthritis by Canadian rheumatologists: a national, multicenter, retrospective cohort. <i>Journal of Rheumatology</i> , 2011 , 38, 2342-5	4.1	13
226	Epidemiologic approaches to infection and immunity: the case of reactive arthritis. <i>Current Opinion in Rheumatology</i> , 2009 , 21, 386-90	5.3	13
225	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. <i>Journal of Psychosomatic Research</i> , 2020 , 135, 110132	4.1	13
224	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.. <i>Lancet Rheumatology, The</i> , 2020 , 2, e743-e753	14.2	13
223	Early Rheumatoid Arthritis Presentation, Treatment, and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study Analysis. <i>Arthritis Care and Research</i> , 2018 , 70, 1245-1250	4.7	13
222	Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021 , 73, 1606-1616	4.7	12
221	Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018 , 45, 456-464	4.1	12
220	Does cigarette smoking mitigate the severity of skin disease in systemic sclerosis?. <i>Rheumatology International</i> , 2013 , 33, 943-8	3.6	12
219	Cross-language measurement equivalence of the Center for Epidemiologic Studies Depression (CES-D) scale in systemic sclerosis: a comparison of Canadian and Dutch patients. <i>PLoS ONE</i> , 2013 , 8, e53923	3.7	12
218	Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: results from the optimization of adalimumab trial. <i>Journal of Rheumatology</i> , 2010 , 37, 2469-74	4.1	12

217	A comparison of health-related quality of life (HRQoL) across four systemic autoimmune rheumatic diseases (SARDs). <i>PLoS ONE</i> , 2017 , 12, e0189840	3.7	12
216	Reduction in Serum Uric Acid May Be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort (CATCH). <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2016 , 9, 37-43	2.3	12
215	The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	12
214	ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI). <i>RMD Open</i> , 2018 , 4, e000738	5.9	12
213	Two-year radiographic and clinical outcomes from the Canadian Methotrexate and Etanercept Outcome study in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2016 , 55, 327-34	3.9	11
212	There is still a care gap in osteoporosis management for patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2014 , 81, 347-51	2.9	11
211	What have multicentre registries across the world taught us about the disease features of systemic sclerosis?. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 169-182	2.3	11
210	Systemic sclerosis immunoglobulin induces growth and a pro-fibrotic state in vascular smooth muscle cells through the epidermal growth factor receptor. <i>PLoS ONE</i> , 2014 , 9, e100035	3.7	11
209	Comprehensive arthritis referral study -- phase 2: analysis of the comprehensive arthritis referral tool. <i>Journal of Rheumatology</i> , 2014 , 41, 1980-9	4.1	11
208	Effect of rheumatologist education on systematic measurements and treatment decisions in rheumatoid arthritis: the metrix study. <i>Journal of Rheumatology</i> , 2012 , 39, 2247-52	4.1	11
207	Systemic sclerosis in Canada's North American Native population: assessment of clinical and serological manifestations. <i>Journal of Rheumatology</i> , 2013 , 40, 1121-6	4.1	11
206	Modeling smoking in systemic sclerosis: a comparison of different statistical approaches. <i>Arthritis Care and Research</i> , 2011 , 63, 570-8	4.7	11
205	Treatment of systemic sclerosis. <i>Current Opinion in Rheumatology</i> , 1993 , 5, 792-801	5.3	11
204	Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. <i>Rheumatology</i> , 2017 , 56, 581-588	3.9	11
203	Increased pigmentation in scleroderma. <i>Journal of Rheumatology</i> , 1996 , 23, 1912-6	4.1	11
202	A randomized double blind trial of verbal NSAID education compared to verbal and written education. <i>Journal of Rheumatology</i> , 1998 , 25, 771-5	4.1	11
201	Best practices in scleroderma: an analysis of practice variability in SSc centres within the Canadian Scleroderma Research Group (CSRG). <i>Clinical and Experimental Rheumatology</i> , 2012 , 30, S38-43	2.2	11
200	A comparison between childhood and adult onset systemic lupus erythematosus adjusted for ethnicity from the 1000 Canadian Faces of Lupus Cohort. <i>Rheumatology</i> , 2019 ,	3.9	10

199	Shortening patient-reported outcome measures through optimal test assembly: application to the Social Appearance Anxiety Scale in the Scleroderma Patient-centered Intervention Network Cohort. <i>BMJ Open</i> , 2019 , 9, e024010	3	10
198	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016 , 68, 167-78	4.7	10
197	The comparability of English, French and Dutch scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F): an assessment of differential item functioning in patients with systemic sclerosis. <i>PLoS ONE</i> , 2014 , 9, e91979	3.7	10
196	Altered salivary redox homeostasis in patients with systemic sclerosis. <i>Journal of Rheumatology</i> , 2010 , 37, 1858-63	4.1	10
195	Differences in disability as measured by the Health Assessment Questionnaire between patients with and without digital ulcers in systemic sclerosis: a post hoc analysis of pooled data from two randomised controlled trials in digital ulcers using bosentan. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 2055-6	2.4	10
194	Squamous cell carcinomas in 2 patients with diffuse scleroderma treated with mycophenolate mofetil. <i>Journal of Rheumatology</i> , 2009 , 36, 460-2	4.1	10
193	Measuring pain in systemic sclerosis: comparison of the short-form McGill Pain Questionnaire versus a single-item measure of pain. <i>Journal of Rheumatology</i> , 2011 , 38, 2581-7	4.1	10
192	Medication use in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2011 , 38, 271-4	4.1	10
191	Increasing treatment in early rheumatoid arthritis is not determined by the disease activity score but by physician global assessment: results from the CATCH study. <i>Journal of Rheumatology</i> , 2012 , 39, 2081-7	4.1	10
190	Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment. <i>Arthritis and Rheumatism</i> , 2008 , 59, 706-13		10
189	Antimitochondrial antibodies and their significance in diffuse and limited scleroderma. <i>Journal of Clinical Rheumatology</i> , 1999 , 5, 206-9	1.1	10
188	Undifferentiated connective tissue disease at risk for systemic sclerosis: Which patients might be labeled prescleroderma?. <i>Autoimmunity Reviews</i> , 2020 , 19, 102659	13.6	10
187	Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity. <i>Arthritis Research and Therapy</i> , 2015 , 17, 343	5.7	9
186	The use of micronutrient supplements is not associated with better quality of life and disease activity in Canadian patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2010 , 37, 87-90	4.1	9
185	An assessment of the measurement equivalence of English and French versions of the Center for Epidemiologic Studies Depression (CES-D) Scale in systemic sclerosis. <i>PLoS ONE</i> , 2014 , 9, e102897	3.7	9
184	Systemic sclerosis: To subset or not to subset, that is the question. <i>European Journal of Rheumatology</i> , 2020 , 7, S222-S227	1.7	9
183	Stress in patients diagnosed with rheumatoid arthritis compared to chronic pain. <i>Rehabilitation Psychology</i> , 2017 , 62, 571-579	2.7	9
182	Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study. <i>Journal of Psychosomatic Research</i> , 2020 , 139, 110262	4.1	9

181	Meta-Analysis of Treatment for Primary Sjögren's Syndrome. <i>Arthritis Care and Research</i> , 2020 , 72, 1011-1021	4.7	9
180	Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years. <i>ACR Open Rheumatology</i> , 2019 , 1, 73-82	3.5	8
179	OP0054 Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 48 Data from the Fassinate Trial. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 87.2-88	2.4	8
178	The future of treatment in systemic sclerosis: can we design better trials?. <i>Lancet Rheumatology, The</i> , 2020 , 2, e185-e194	14.2	8
177	Repeat Testing of Antibodies and Complements in Systemic Lupus Erythematosus: When Is It Enough?. <i>Journal of Rheumatology</i> , 2018 , 45, 827-834	4.1	8
176	High Adherence to System-Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years. <i>Arthritis Care and Research</i> , 2018 , 70, 842-850	4.7	8
175	Summed and Weighted Summary Scores for the Medsger Disease Severity Scale Compared with the Physician's Global Assessment of Disease Severity in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2016 , 43, 1510-8	4.1	8
174	Using Marital Status and Continuous Marital Satisfaction Ratings to Predict Depressive Symptoms in Married and Unmarried Women With Systemic Sclerosis: A Canadian Scleroderma Research Group Study. <i>Arthritis Care and Research</i> , 2016 , 68, 1143-9	4.7	8
173	Development and Validation of the Body Concealment Scale for Scleroderma. <i>Arthritis Care and Research</i> , 2016 , 68, 1158-65	4.7	8
172	Pragmatism of Randomized Controlled Trials of Biologic Treatment With Methotrexate in Rheumatoid Arthritis: A Systematic Review. <i>Arthritis Care and Research</i> , 2019 , 71, 620-628	4.7	8
171	Cardiovascular disease after Escherichia coli O157:H7 gastroenteritis. <i>Cmaj</i> , 2013 , 185, E70-7	3.5	8
170	Canadian recommendations for clinical trials of pharmacologic interventions in rheumatoid arthritis: inclusion criteria and study design. <i>Journal of Rheumatology</i> , 2011 , 38, 2095-104	4.1	8
169	Patients with systemic autoimmune diseases could not distinguish comorbidities from their index disease. <i>Journal of Clinical Epidemiology</i> , 2008 , 61, 654-62	5.7	8
168	The temporal relationship of Raynaud's phenomenon and features of connective tissue disease in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008 , 35, 2329-33	4.1	8
167	Persistent Disease Activity Remains a Burden for Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2019 , 46, 166-175	4.1	8
166	Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. <i>Rheumatology</i> , 2020 , 59, 398-406	3.9	8
165	Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort. <i>Rheumatology</i> , 2017 , 56, 1111-1122	3.9	7
164	The durability of abatacept as a first and subsequent biologic and improvement in HAQ from a large multi-site real-world study. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 44, 499-505	5.3	7

163	Mentoring women in medicine: a personal perspective. <i>Lancet, The</i> , 2018 , 391, 520-521	4.0	7
162	Exercise habits and factors associated with exercise in systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. <i>Disability and Rehabilitation</i> , 2018 , 40, 1997-2003	2.4	7
161	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018 , 57, 152-157	3.9	7
160	Assessment of reproductive history in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1661-4		7
159	A meta-analysis of the epidemiology of giant cell arteritis across time and space. <i>Arthritis Research and Therapy</i> , 2021 , 23, 82	5.7	7
158	Mood, Disability, and Quality of Life among a Subgroup of Rheumatoid Arthritis Individuals with Experiential Avoidance and Anxiety Sensitivity. <i>Pain Research and Management</i> , 2016 , 2016, 7241856	2.6	7
157	Planning for the Rheumatologist Workforce: Factors Associated With Work Hours and Volumes. <i>Journal of Clinical Rheumatology</i> , 2019 , 25, 142-146	1.1	7
156	Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort. <i>Arthritis Care and Research</i> , 2020 , 72, 1104-1111	4.7	7
155	Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 2197-2207	7.4	7
154	The relationship between NSAID use and osteoarthritis (OA) severity in patients with hip and knee OA: results of a case control study of NSAID use comparing those requiring hip and knee replacements to those in whom surgery was not recommended. <i>Medical Science Monitor</i> , 2008 , 14, CR604-10	3.2	7
153	Emerging drugs and therapeutics for systemic sclerosis. <i>Expert Opinion on Emerging Drugs</i> , 2016 , 21, 421-430	3.7	6
152	Severe myositis of the hip flexors after pre-operative chemoradiation therapy for locally advanced rectal cancer: case report. <i>BMC Cancer</i> , 2016 , 16, 243	4.8	6
151	Prevalence and Characteristics of Metabolic Syndrome Differ in Men and Women with Early Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2019 , 1, 535-541	3.5	6
150	Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort. <i>Rheumatology</i> , 2014 , 53, 482-90	3.9	6
149	Correlations between changes in cytokines and clinical outcomes for early phase (proof of concept) trials in active diffuse systemic sclerosis using data from an imatinib study. <i>Rheumatology</i> , 2014 , 53, 1830-4	3.9	6
148	The association between disease activity and duration in systemic sclerosis. <i>Journal of Rheumatology</i> , 2010 , 37, 2299-306	4.1	6
147	Raynaud's phenomenon (primary). <i>Clinical Evidence</i> , 2013 , 2013, 1119		6
146	Psychological Distress in Out-Patients Assessed for Chronic Pain Compared to Those with Rheumatoid Arthritis. <i>Pain Research and Management</i> , 2016 , 2016, 7071907	2.6	6

145	Incidence and prevalence of giant cell arteritis in Ontario, Canada. <i>Rheumatology</i> , 2020 , 59, 3250-3258	3.9	6
144	A Delphi exercise and cluster analysis to aid in the development of potential classification criteria for systemic sclerosis using SSc experts and databases. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, 24-30	2.2	6
143	Thresholds for the 28-joint disease activity score (DAS28) using C-reactive protein are lower compared to DAS28 using erythrocyte sedimentation rate in early rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 799-803	2.2	6
142	The association of sociodemographic and objectively-assessed disease variables with fatigue in systemic sclerosis: an analysis of 785 Canadian Scleroderma Research Group Registry patients. <i>Clinical Rheumatology</i> , 2017 , 36, 373-379	3.9	5
141	Management of Raynaud's phenomenon in systemic sclerosis-a practical approach.. <i>Journal of Scleroderma and Related Disorders</i> , 2019 , 4, 102-110	2.3	5
140	Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial. <i>Rheumatology and Therapy</i> , 2019 , 6, 409-419	4.4	5
139	Physical or Occupational Therapy Use in Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. <i>Journal of Rheumatology</i> , 2019 , 46, 1605-1613	4.1	5
138	Evolving patterns of reactive arthritis. <i>Clinical Rheumatology</i> , 2019 , 38, 2083-2088	3.9	5
137	Encounters with Rheumatologists in a Publicly Funded Canadian Healthcare System: A Population-based Study. <i>Journal of Rheumatology</i> , 2020 , 47, 468-476	4.1	5
136	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1646-1652	4.7	5
135	How to Attract Trainees, a Pan-Canadian Perspective: Phase 1 of the "Training the Rheumatologists of Tomorrow" Project. <i>Journal of Rheumatology</i> , 2016 , 43, 788-98	4.1	5
134	Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years. <i>Rheumatology</i> , 2020 , 59, 568-574	3.9	5
133	Social persuasion in rheumatology: a randomized trial of testimonials on television in the rheumatology clinic waiting room to increase attendance for multidisciplinary education. <i>Rheumatology International</i> , 2014 , 34, 903-7	3.6	5
132	Demographic and clinical factors associated with physician service use in systemic sclerosis. <i>Journal of Rheumatology</i> , 2009 , 36, 96-8	4.1	5
131	Health Assessment Questionnaire at One Year Predicts All-Cause Mortality in Patients With Early Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 197-202	9.5	5
130	Improvements in Fatigue Lag Behind Disease Remission in Early Rheumatoid Arthritis: Results From the Canadian Early Arthritis Cohort. <i>Arthritis and Rheumatology</i> , 2021 , 73, 53-60	9.5	5
129	Scleroderma epidemiology update. <i>Current Opinion in Rheumatology</i> , 2021 , 33, 122-127	5.3	5
128	Association of Arthritis Onset with Influenza: Analysis of the Canadian Early Inflammatory Arthritis Cohort. <i>ACR Open Rheumatology</i> , 2019 , 1, 63-69	3.5	4

127	Can the Cancer-related Fatigue Case-definition Criteria Be Applied to Chronic Medical Illness? A Comparison between Breast Cancer and Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2015 , 42, 1156-62	4.1	4
126	Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort. <i>Journal of Rheumatology</i> , 2015 , 42, 2023-8	4.1	4
125	Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS). <i>Arthritis Research and Therapy</i> , 2020 , 22, 132	5.7	4
124	Physician global assessments for disease activity in rheumatoid arthritis are all over the map!. <i>RMD Open</i> , 2018 , 4, e000578	5.9	4
123	Low prevalence of work disability in early inflammatory arthritis (EIA) and early rheumatoid arthritis at enrollment into a multi-site registry: results from the catch cohort. <i>Rheumatology International</i> , 2013 , 33, 457-65	3.6	4
122	The revised BILAG Index with numerical scoring in systemic lupus erythematosus: added value with some limitations. <i>Rheumatology</i> , 2010 , 49, 1616-7	3.9	4
121	Does C-reactive protein add value in active rheumatoid arthritis? Results from the Optimization of Humira Trial. <i>Scandinavian Journal of Rheumatology</i> , 2011 , 40, 232-3	1.9	4
120	The sensitivity and specificity of pain diagrams in rheumatic disease referrals. <i>Rheumatology</i> , 2012 , 51, 1093-8	3.9	4
119	Results of a Pilot Randomized Placebo-Controlled Trial in Primary and Secondary Raynaud's Phenomenon with St. John's Wort: Detecting Changes in Angiogenic Cytokines When RP Improves. <i>ISRN Rheumatology</i> , 2011 , 2011, 580704		4
118	Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2020 , 59, 1715-1724	3.9	4
117	Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc). <i>Autoimmunity Reviews</i> , 2020 , 19, 102602	13.6	4
116	Dispositional Affect in Unique Subgroups of Patients with Rheumatoid Arthritis. <i>Pain Research and Management</i> , 2016 , 2016, 1024985	2.6	4
115	Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2021 , 48, 852-858	4.1	4
114	Evaluation of Rheumatology Workforce Supply Changes in Ontario, Canada, from 2000 to 2030. <i>Healthcare Policy</i> , 2021 , 16, 119-134	1.1	4
113	Flibanserin. <i>Journal of Pharmacy Practice</i> , 2017 , 30, 256-260	1.3	3
112	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. <i>Body Image</i> , 2017 , 20, 99-106	7.4	3
111	Connective tissue disease: Reflections on the EULAR recommendations for the treatment of systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2017 , 13, 134-136	8.1	3
110	An evidence-based strategy to screen for pulmonary arterial hypertension in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1421-1427	5.3	3

109	The rapid kinetics of optimal treatment with subcutaneous methotrexate in early inflammatory arthritis: an observational study. <i>BMC Musculoskeletal Disorders</i> , 2016 , 17, 364	2.8	3
108	Collection of antirheumatic medication data from both patients and rheumatologists shows strong agreement in a real-world clinical cohort: the Ontario Best Practices Research Initiative-a rheumatoid arthritis cohort. <i>Journal of Clinical Epidemiology</i> , 2019 , 114, 95-103	5.7	3
107	Specificity of Systemic Sclerosis Classification Criteria. <i>Journal of Rheumatology</i> , 2015 , 42, 2512	4.1	3
106	Validity of self-reported comorbidities in systemic sclerosis. <i>Journal of Rheumatology</i> , 2009 , 36, 1477-80	4.1	3
105	Sample size calculations in scleroderma: a rational approach to choosing outcome measurements in scleroderma trials. <i>Clinical and Investigative Medicine</i> , 1995 , 18, 1-10	0.9	3
104	Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis for Function and Pain is Affected by Rheumatoid Factor. <i>Open Rheumatology Journal</i> , 2014 , 8, 73-6	0.2	3
103	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. <i>JMIR Research Protocols</i> , 2020 , 9, e16799	2	3
102	Feminization of the Rheumatology Workforce: A Longitudinal Evaluation of Patient Volumes, Practice Sizes, and Physician Remuneration. <i>Journal of Rheumatology</i> , 2021 , 48, 1090-1097	4.1	3
101	The frequency of uveitis in patients with adult versus childhood spondyloarthritis. <i>RMD Open</i> , 2020 , 6,	5.9	3
100	Rheumatoid arthritis: TNF inhibitors and cardiovascular risk management in RA. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 317-8	8.1	3
99	Palindromic Rheumatism Frequently Precedes Early Rheumatoid Arthritis: Results From an Incident Cohort. <i>ACR Open Rheumatology</i> , 2019 , 1, 614-619	3.5	3
98	Patient perception of disease burden in diffuse cutaneous systemic sclerosis.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 66-76	2.3	3
97	Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study. <i>Journal of Psychosomatic Research</i> , 2021 , 140, 110314	4.1	3
96	Health Literacy Rates in a Population of Patients with Rheumatoid Arthritis in Southwestern Ontario. <i>Journal of Rheumatology</i> , 2015 , 42, 1610-5	4.1	2
95	Appropriateness of laboratory tests in the diagnosis of inflammatory rheumatic diseases among patients newly referred to rheumatologists. <i>Joint Bone Spine</i> , 2020 , 87, 588-595	2.9	2
94	Factor structure and convergent validity of the Derriford Appearance Scale-24 using standard scoring versus treating 'not applicable' responses as missing data: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. <i>BMJ Open</i> , 2018 , 8, e018641	3	2
93	FRI0066 The 28-Joint Disease Activity Score (DAS28) Using C-Reactive Protein Yields Lower Thresholds Compared To Conventional DAS28 with Erythrocyte Sedimentation Rate in Early Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 449.3-450	2.4	2
92	The contemporary management of systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 573-582	5.1	2

91	Vaccination Guidelines for Patients with Immune-Mediated Disorders on Immunosuppressive Therapies-Executive Summary. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019 , 2, 149-152 ^{0.5}	2
90	Joint Estimation of Remission and Response for Methotrexate-Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis. <i>ACR Open Rheumatology</i> , 2019 , 1, 471-479	3.5 2
89	Predicting Low Disease State and Remission in Early Rheumatoid Arthritis in the First Six Months, Comparing the Simplified Disease Activity Index and European League Against Rheumatism Response Measures: Results From an Early Arthritis Cohort. <i>Arthritis Care and Research</i> , 2017 , 69, 737-741	4.7 2
88	Drug interventions versus placebo for the treatment of Raynaud's phenomenon: generic protocol. <i>The Cochrane Library</i> , 2015 ,	5.2 2
87	Disease modification and other trials in systemic sclerosis have come a long way, but have to go further. <i>Arthritis Care and Research</i> , 2012 , 64, 955-9	4.7 2
86	Ottawa, Ontario, Canada, February 13-16, 2013. <i>Journal of Rheumatology</i> , 2013 , 40, 950-1025	4.1 2
85	Potential effects of a national consensus statement on optimal treatment of early rheumatoid arthritis in Ontario. <i>Scandinavian Journal of Rheumatology</i> , 2009 , 38, 390-1	1.9 2
84	Do patients with active RA have differences in disease activity and perceptions if anti-TNF naïve versus anti-TNF experienced? Baseline results of the optimization of adalimumab trial. <i>Medical Science Monitor</i> , 2012 , 18, PI17-20	3.2 2
83	Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e844-e854	14.2 2
82	Assessing differential item functioning for the Social Appearance Anxiety Scale: a Scleroderma patient-centred Intervention Network (SPIN) Cohort Study. <i>BMJ Open</i> , 2020 , 10, e037639	3 2
81	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. <i>Journal of Rheumatology</i> , 2021 , 48, 1698-1717	4.1 2
80	Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift). <i>RMD Open</i> , 2021 , 7,	5.9 2
79	OP0315 ACHIEVING A LOW DISEASE STATE WITHIN FIRST 3 MONTHS IN EARLY RHEUMATOID ARTHRITIS RESULTS IN LOWER FATIGUE OVER 5 YEARS 2019 ,	2
78	An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs. <i>Rheumatology</i> , 2020 , 59, 1522-1528	3.9 2
77	Pain and Self-Efficacy Among Patients With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Nursing Research</i> , 2021 , 70, 334-343	1.9 2
76	Raynaud's phenomenon (primary). <i>Clinical Evidence</i> , 2003 , 1339-48	2
75	A comparison between general rheumatologists and scleroderma experts with respect to following systemic sclerosis guidelines. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, S40-6	2.2 2
74	Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results. <i>Journal of Rheumatology</i> , 2019 , 46, 874-886	4.1 1

73	Response to: 'drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?' by Dr Boers. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e34	2.4	1
72	Randomized Trials, Meta-Analyses, and Systematic Reviews: Using Examples from Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2018 , 44, 295-305	2.4	1
71	A153: Long-term Outcomes of Childhood-Onset Systemic Lupus Erythematosus in Adulthood. <i>Arthritis and Rheumatology</i> , 2014 , 66, S198-S198	9.5	1
70	Response to: 'Are autoantibodies to RNA-polymerase III to be incorporated in routine diagnostic laboratory algorithms for systemic autoimmune rheumatic diseases?' by Jan Damoiseaux. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e30	2.4	1
69	A randomized, single-blinded cross-over trial of ischemic preconditioning in Raynaud's phenomenon. <i>Journal of Scleroderma and Related Disorders</i> , 2017 , 2, 213-220	2.3	1
68	FRI0241 Association of gastroesophageal factors and progression of interstitial lung disease in the canadian scleroderma research group (CSRG); a large, multi-center database. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 395.3-396	2.4	1
67	Observational data to study medication outcomes in systemic sclerosis. <i>Journal of Rheumatology</i> , 2011 , 38, 575-7	4.1	1
66	Convergence paralysis as a manifestation of polyarteritis nodosa. <i>Canadian Journal of Neurological Sciences</i> , 2006 , 33, 423-5	1	1
65	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. <i>Trials</i> , 2021 , 22, 856	2.8	1
64	Estimating Benefits from Immunosuppressive Treatment in Diffuse Cutaneous Systemic Sclerosis: Data from the Canadian Scleroderma Research Group. <i>Open Journal of Rheumatology and Autoimmune Diseases</i> , 2014 , 04, 248-253	0.2	1
63	Possible benefit of tadalafil cream for the treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis. <i>Clinical Rheumatology</i> , 2020 , 39, 963-965	3.9	1
62	Systemic Sclerosis 2013 , 955-969		1
61	Patient and Rheumatologist Perspectives on Tapering DMARDs in Rheumatoid Arthritis: A Qualitative Study. <i>Rheumatology</i> , 2021 ,	3.9	1
60	Reply. <i>Arthritis Care and Research</i> , 2016 , 68, 1053-4	4.7	1
59	OP0068 ABATACEPT IN EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: RESULTS OF A PHASE 2 INVESTIGATOR-INITIATED, MULTICENTER, DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL 2019 ,		1
58	Factors associated with patient-reported likelihood of using online self-care interventions: a Scleroderma Patient-centered Intervention Network (SPIN) cohort study. <i>BMJ Open</i> , 2019 , 9, e029542	3	1
57	A quarter of patients time their early rheumatoid arthritis onset differently than physicians. <i>RMD Open</i> , 2019 , 5, e000931	5.9	1
56	Increased mortality for individuals with Giant Cell Arteritis: a population-based study. <i>Arthritis Care and Research</i> , 2021 ,	4.7	1

55	Treatment of osteoarthritis of the hip and knee: a comparison of NSAID use in patients for whom surgery was and was not recommended. <i>Clinical and Experimental Rheumatology</i> , 2004 , 22, 171-6	2.2	1
54	Giant Calcinosis in Dermatomyositis and Scleroderma Overlap. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1236	9.5	0
53	Comment on: Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis: reply. <i>Rheumatology</i> , 2020 , 59, 1783-1784	3.9	0
52	A cluster of non-tuberculosis mycobacterial infections in patients with connective tissue diseases. <i>Medicina Clínica</i> , 2020 , 154, 468-469	1	0
51	Authors' Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis. <i>Advances in Therapy</i> , 2021 , 38, 2750-2756 ^O	4.1	0
50	Systemic Sclerosis and Associated Interstitial Lung Disease in Ontario, Canada: An Examination of Prevalence and Survival Over 10 Years. <i>Journal of Rheumatology</i> , 2021 , 48, 1427-1434	4.1	0
49	Osteoporosis and osteonecrosis in systemic lupus erythematosus. <i>Revista Colombiana De Reumatología</i> , 2021 , 28, 3-11	0.2	0
48	Prevalence of Renal Impairment in a US Commercially Insured Rheumatoid Arthritis Population: A Retrospective Analysis. <i>Rheumatology and Therapy</i> , 2021 , 8, 1383-1391	4.4	0
47	Counselling patients for return to work on immunosuppression: practices of Canadian specialists during the COVID-19 pandemic. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 874-878	2.2	0
46	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. <i>Pilot and Feasibility Studies</i> , 2022 , 8, 45	1.9	0
45	European consensus statements for interstitial lung disease in systemic sclerosis. <i>Lancet Rheumatology, The</i> , 2020 , 2, e318-e319	14.2	
44	FRI0269 Diffuse Cutaneous Systemic Sclerosis (dcSSc) Referral and Diagnosis: Results of A Survey of Healthcare Providers. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 532.1-532	2.4	
43	AB0206 Treatment Patterns in Rheumatoid Arthritis after Methotrexate: Data from The Ontario Best Practice Research Initiatives Cohort. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 967.3-968	2.4	
42	OP0173 How Much of A Barrier Is Excess Weight and Smoking for Achieving Sustained Remission in Early RA? Results from The Canadian Early Arthritis Cohort. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 121.2-121	2.4	
41	Reply. <i>Arthritis Care and Research</i> , 2016 , 68, 1385-6	4.7	
40	How low can we go for continued dosing of rituximab in rheumatoid arthritis?. <i>Lancet Rheumatology, The</i> , 2019 , 1, e134-e135	14.2	
39	Lacunes dans la prise en charge de l'ostéoporose chez les patients atteints de polyarthrite rhumatoïde. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014 , 81, 413-417	0.1	
38	SAT0587 A Comparative Study of Rheumatology Specialist Training across UK and Canada. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 802.2-802	2.4	

37	FRI0371 A Comparison of Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) TRIAL Design: Ways to Improve Positive Trials in Sle. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 521.1-521	2.4
36	OP0200 Thromboembolism in Rheumatology: Investigation of the Risks of Deep Vein Thrombosis and Pulmonary Embolism in Inflammatory Arthritis, Connective Tissue Diseases, Vasculitis and Myositis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 138.2-138	2.4
35	AB0251 The Impact of Missing Anti-Citrullinated Protein Antibody (ACPA) Serology on Outcomes in Early Rheumatoid Arthritis: Results from Catch (Canadian Early Arthritis Cohort). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 886.2-887	2.4
34	SAT0119 Prevalence of Cardiovascular Disease and its Associations with Disease Severity in Rheumatoid Arthritis Patients [Data from the Ontario Best Practices Research Initiative (OBRI)]. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 693.2-693	2.4
33	Lessons learned from Canadian databases in RA, SLE and systemic sclerosis: highlights from the Canadian Rheumatology Association Annual Scientific Meeting. <i>International Journal of Clinical Rheumatology</i> , 2015 , 10, 135-137	1.5
32	THU0337 Worse Disease Trajectory in Early RA Patients is Associated with Lower Improvements in Health Related Quality of Life; Results from a Multicenter Early RA Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 317.2-318	2.4
31	SAT0347 Comparisons of Reporting and Level of Agreement of Co-Morbidities Ascertained from Rheumatologists, Patients and Health Administrative Data: A Data Linkage Study Among Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 784.2-785	2.4
30	Drug Treatment of Raynaud's Phenomenon 2015 , 315-337	
29	THU0412 Cardiovascular Outcomes in Patients with Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-Analyses. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 324.2-325 ^{2.4}	2.4
28	Issues in Clinical Trial Design 2012 , 651-660	
27	Updated systemic sclerosis criteria improve disease classification. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2013 , 74, 609-609	0.8
26	OP0257 IL-6 in scleroderma; potential implications for targeted therapy: A systematic analysis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 143.1-143	2.4
25	FRI0187 The effectiveness of abatacept in a large RA real world database including durability and changes in haq over time: Post DMARDs and post TNF. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 375.3-376 ^{2.4}	2.4
24	SAT0101 Das does not predict increasing treatment in early rheumatoid arthritis (ERA): Results from the catch study. <i>Annals of the Rheumatic Diseases</i> , 2013 , 71, 504.2-504	2.4
23	Systemic Sclerosis (Scleroderma) and Raynaud's Phenomenon 2009 , 77-95	
22	Sexual function in women with systemic sclerosis: Comment on the article by Schouffoer et al. <i>Arthritis Care and Research</i> , 2010 , 62, 1200; author reply 1200-1	4.7
21	Frequency of adverse drug reactions (ADRS) in SLE. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 73, P54-P54	6.1
20	The Canadian Consensus Working Group's Approach to Identifying and Managing Statin-Associated Muscle and Other Symptoms. <i>Contemporary Cardiology</i> , 2020 , 137-150	0.1

19	Measurement in Scleroderma Clinical Trials 2000 , 183-203	
18	SEQUENCE OF VARIABLES IN THE DIMENSIONAL SET 2007 , 381-400	
17	Arthritis in Systemic Sclerosis. <i>In Clinical Practice</i> , 2021 , 339-362	0
16	Renal calcification 276-281	
15	PROMs for Systemic Sclerosis (Scleroderma) 2016 , 287-307	
14	A Needs-Based Rheumatologist Education Program on Treating to Target in Psoriatic Arthritis and Spondyloarthritis: Insights and Challenges. <i>Open Journal of Rheumatology and Autoimmune Diseases</i> , 2017 , 07, 53-64	0.2
13	A Middle-Aged Male Scleroderma Patient Who Can No Longer Perform His Occupation 2011 , 281-292	
12	Skin Manifestations and Musculoskeletal Disease in SSc 2014 , 23-36	
11	Immunoglobulin G-related disease as a mimicker of granulomatosis with polyangiitis: a case report. <i>Scandinavian Journal of Rheumatology</i> , 2020 , 49, 163-164	1.9
10	An Update of Outcome Measures in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2020 , 72 Suppl 10, 110-133	4.7
9	Comment on: Incidence and prevalence of giant cell arteritis in Ontario, Canada: reply. <i>Rheumatology</i> , 2020 , 59, e123-e124	3.9
8	Pertinence des tests de laboratoire dans le diagnostic des rhumatismes inflammatoires chez des patients nouvellement orientés vers un rhumatologue. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2021 , 88, 208-215	0.1
7	Dr. Roubille, et al reply. <i>Journal of Rheumatology</i> , 2016 , 43, 993-4	4.1
6	Reply. <i>Arthritis and Rheumatology</i> , 2019 , 71, 834-835	9.5
5	Time to remission in swollen joints is far faster than patient reported outcomes in rheumatoid arthritis: results from the Ontario Best Practices Research Initiative (OBRI). <i>Rheumatology</i> , 2021 , 60, 717-727	3.9
4	Metrics and Outcomes of Systemic Lupus Erythematosus in Clinical Practice 2021 , 391-402	
3	Immunosuppression use in early systemic sclerosis may be increasing over time.. <i>Journal of Scleroderma and Related Disorders</i> , 2022 , 7, 33-41	2.3
2	Changes in Market Share of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Results from the Ontario Best-Practice Research Initiative Database. <i>Current Rheumatology Reviews</i> , 2021 , 17, 349-359	1.6

1 Systemic Sclerosis443-493